SOUTH AFRICA – Following news that French pharmaceutical corporation Sanofi will abandon its promising mRNA COVID-19 vaccine candidate, Médecins Sans Frontières (MSF) has urged the corporation to transfer the technology and know-how for the vaccine to the World Health Organization (WHO)-led COVID-19 mRNA vaccine technology transfer hub in South Africa.
“It’s unconscionable for Sanofi to let a promising vaccine candidate gather dust on its shelves simply because it won’t be lucrative for them, when they have an opportunity to put this research to lifesaving use by transferring their know-how to the WHO mRNA vaccine hub in South Africa,” Alain Alsalhani, Vaccines and Special Projects Pharmacist at MSF’s Access Campaign said.
Since its announcement in April 2021, the WHO mRNA hub has yet to receive any technology transfers and is now resorting to attempting to develop its own mRNA COVID-19 vaccine candidate from scratch – a lengthy, unnecessarily duplicative process.
This despite two approved mRNA vaccines and 13 candidates in advanced stages of development in existence which could be shared through the hub with producers in South Africa and other low- and middle-income countries.
Any mRNA know-how shared with the WHO hub could save time and help the hub’s efforts towards developing a safe and effective mRNA vaccine for low- and middle-income countries.
Sanofi announced that it will not pursue the development of its mRNA candidate vaccine only a few hours after publishing a press release announcing positive Phase 1/2 study interim results.
Although more detailed results are still to come, Sanofi said “we are happy to see these positive results” and that these “confirm the potential” of the platform.
The decision to abandon their COVID-19 mRNA candidate was justified by the mRNA COVID-19 vaccines market already being dominated by its competitors Pfizer/-BioNTech and Moderna. Sanofi has stated it will instead start developing a flu vaccine using this same mRNA platform.
Sanofi received US$31 million in public funding for its COVID-19 vaccine development programme, and a further US$4.9 billion in advance purchase agreements, which significantly de-risked the research and development for the corporation.
Transferring Sanofi’s mRNA platform to the WHO hub could boost and accelerate the hub’s R&D efforts by giving access to the technical and clinical data generated by Sanofi thus far.
Moreover, Sanofi as a global pharmaceutical actor should assist the hub in getting access to key starting materials for mRNA vaccine development and production.
If successful, the hub would then assist multiple able manufacturers in low- and middle-income countries to start production of COVID-19 and other mRNA-based vaccines for the current and future pandemics.
“We urge Sanofi to transfer its technology to the WHO mRNA vaccine hub, to boost and accelerate its efforts towards developing an mRNA platform for vaccine production, not just for COVID but other infectious diseases as well, that can then be transferred to manufacturers in low- and middle-income countries,” Alsalhani said.